Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity

Taiji Tsunemi, Tamara Perez-Rosello, Yuta Ishiguro, Asako Yoroisaka, Sohee Jeon, Kana Hamada, Malini Rammonhan, Yvette C. Wong, Zhong Xie, Wado Akamatsu, Joe Mazzulli, Dalton James Surmeier Jr, Nobutaka Hattori, Dimitri Krainc

Research output: Contribution to journalArticle

Abstract

The accumulation of misfolded proteins is a common pathological feature of many neurodegenerative disorders, including synucleinopathies such as Parkinson's disease (PD), which is characterized by the presence of α-synuclein (α-syn)-containing Lewy bodies. However, although recent studies have investigated α-syn accumulation and propagation in neurons, the molecular mechanisms underlying α-syn transmission have been largely unexplored. Here, we examined a monogenic form of synucleinopathy caused by loss-of-function mutations in lysosomal ATP13A2/PARK9. These studies revealed that lysosomal exocytosis regulates intracellular levels of α-syn in human neurons. Loss of PARK9 function in patient-derived dopaminergic neurons disrupted lysosomal Ca2+ homeostasis, reduced lysosomal Ca2+ storage, increased cytosolic Ca2+, and impaired lysosomal exocytosis. Importantly, this dysfunction in lysosomal exocytosis impaired α-syn secretion from both axons and soma, promoting α-syn accumulation. However, activation of the lysosomal Ca2+ channel transient receptor potential mucolipin 1 (TRPML1) was sufficient to upregulate lysosomal exocytosis, rescue defective α-syn secretion, and prevent α-syn accumulation. Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies.SIGNIFICANCE STATEMENT Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons. However, it is unclear what the mechanism might be. Here, we demonstrate a novel role for lysosomal exocytosis in clearing intracellular α-syn and show that impairment of this pathway by mutations in the PD-linked gene ATP13A2/PARK9 contributes to α-syn accumulation in human dopaminergic neurons. Importantly, upregulating lysosomal exocytosis by increasing lysosomal Ca2+ levels was sufficient to rescue defective α-syn secretion and accumulation in patient neurons. These studies identify lysosomal exocytosis as a potential therapeutic target in diseases characterized by the accumulation of α-syn, including PD.

Original languageEnglish (US)
Pages (from-to)5760-5772
Number of pages13
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience
Volume39
Issue number29
DOIs
StatePublished - Jul 17 2019

Fingerprint

Synucleins
Dopaminergic Neurons
Exocytosis
Parkinson Disease
Neurons
Neurodegenerative Diseases
Transient Receptor Potential Channels
Lewy Bodies
Mutation
Carisoprodol
Axons
Homeostasis
Up-Regulation

Keywords

  • Kufor–Rakeb syndrome
  • Parkinson's disease
  • TRPML1
  • alpha synuclein
  • dopaminergic neuron
  • lysosomal exocytosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Tsunemi, Taiji ; Perez-Rosello, Tamara ; Ishiguro, Yuta ; Yoroisaka, Asako ; Jeon, Sohee ; Hamada, Kana ; Rammonhan, Malini ; Wong, Yvette C. ; Xie, Zhong ; Akamatsu, Wado ; Mazzulli, Joe ; Surmeier Jr, Dalton James ; Hattori, Nobutaka ; Krainc, Dimitri. / Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity. In: The Journal of neuroscience : the official journal of the Society for Neuroscience. 2019 ; Vol. 39, No. 29. pp. 5760-5772.
@article{0b04183d09b844eeb5afe4790a9009be,
title = "Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity",
abstract = "The accumulation of misfolded proteins is a common pathological feature of many neurodegenerative disorders, including synucleinopathies such as Parkinson's disease (PD), which is characterized by the presence of α-synuclein (α-syn)-containing Lewy bodies. However, although recent studies have investigated α-syn accumulation and propagation in neurons, the molecular mechanisms underlying α-syn transmission have been largely unexplored. Here, we examined a monogenic form of synucleinopathy caused by loss-of-function mutations in lysosomal ATP13A2/PARK9. These studies revealed that lysosomal exocytosis regulates intracellular levels of α-syn in human neurons. Loss of PARK9 function in patient-derived dopaminergic neurons disrupted lysosomal Ca2+ homeostasis, reduced lysosomal Ca2+ storage, increased cytosolic Ca2+, and impaired lysosomal exocytosis. Importantly, this dysfunction in lysosomal exocytosis impaired α-syn secretion from both axons and soma, promoting α-syn accumulation. However, activation of the lysosomal Ca2+ channel transient receptor potential mucolipin 1 (TRPML1) was sufficient to upregulate lysosomal exocytosis, rescue defective α-syn secretion, and prevent α-syn accumulation. Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies.SIGNIFICANCE STATEMENT Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons. However, it is unclear what the mechanism might be. Here, we demonstrate a novel role for lysosomal exocytosis in clearing intracellular α-syn and show that impairment of this pathway by mutations in the PD-linked gene ATP13A2/PARK9 contributes to α-syn accumulation in human dopaminergic neurons. Importantly, upregulating lysosomal exocytosis by increasing lysosomal Ca2+ levels was sufficient to rescue defective α-syn secretion and accumulation in patient neurons. These studies identify lysosomal exocytosis as a potential therapeutic target in diseases characterized by the accumulation of α-syn, including PD.",
keywords = "Kufor–Rakeb syndrome, Parkinson's disease, TRPML1, alpha synuclein, dopaminergic neuron, lysosomal exocytosis",
author = "Taiji Tsunemi and Tamara Perez-Rosello and Yuta Ishiguro and Asako Yoroisaka and Sohee Jeon and Kana Hamada and Malini Rammonhan and Wong, {Yvette C.} and Zhong Xie and Wado Akamatsu and Joe Mazzulli and {Surmeier Jr}, {Dalton James} and Nobutaka Hattori and Dimitri Krainc",
year = "2019",
month = "7",
day = "17",
doi = "10.1523/JNEUROSCI.3085-18.2019",
language = "English (US)",
volume = "39",
pages = "5760--5772",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "29",

}

Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity. / Tsunemi, Taiji; Perez-Rosello, Tamara; Ishiguro, Yuta; Yoroisaka, Asako; Jeon, Sohee; Hamada, Kana; Rammonhan, Malini; Wong, Yvette C.; Xie, Zhong; Akamatsu, Wado; Mazzulli, Joe; Surmeier Jr, Dalton James; Hattori, Nobutaka; Krainc, Dimitri.

In: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 39, No. 29, 17.07.2019, p. 5760-5772.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity

AU - Tsunemi, Taiji

AU - Perez-Rosello, Tamara

AU - Ishiguro, Yuta

AU - Yoroisaka, Asako

AU - Jeon, Sohee

AU - Hamada, Kana

AU - Rammonhan, Malini

AU - Wong, Yvette C.

AU - Xie, Zhong

AU - Akamatsu, Wado

AU - Mazzulli, Joe

AU - Surmeier Jr, Dalton James

AU - Hattori, Nobutaka

AU - Krainc, Dimitri

PY - 2019/7/17

Y1 - 2019/7/17

N2 - The accumulation of misfolded proteins is a common pathological feature of many neurodegenerative disorders, including synucleinopathies such as Parkinson's disease (PD), which is characterized by the presence of α-synuclein (α-syn)-containing Lewy bodies. However, although recent studies have investigated α-syn accumulation and propagation in neurons, the molecular mechanisms underlying α-syn transmission have been largely unexplored. Here, we examined a monogenic form of synucleinopathy caused by loss-of-function mutations in lysosomal ATP13A2/PARK9. These studies revealed that lysosomal exocytosis regulates intracellular levels of α-syn in human neurons. Loss of PARK9 function in patient-derived dopaminergic neurons disrupted lysosomal Ca2+ homeostasis, reduced lysosomal Ca2+ storage, increased cytosolic Ca2+, and impaired lysosomal exocytosis. Importantly, this dysfunction in lysosomal exocytosis impaired α-syn secretion from both axons and soma, promoting α-syn accumulation. However, activation of the lysosomal Ca2+ channel transient receptor potential mucolipin 1 (TRPML1) was sufficient to upregulate lysosomal exocytosis, rescue defective α-syn secretion, and prevent α-syn accumulation. Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies.SIGNIFICANCE STATEMENT Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons. However, it is unclear what the mechanism might be. Here, we demonstrate a novel role for lysosomal exocytosis in clearing intracellular α-syn and show that impairment of this pathway by mutations in the PD-linked gene ATP13A2/PARK9 contributes to α-syn accumulation in human dopaminergic neurons. Importantly, upregulating lysosomal exocytosis by increasing lysosomal Ca2+ levels was sufficient to rescue defective α-syn secretion and accumulation in patient neurons. These studies identify lysosomal exocytosis as a potential therapeutic target in diseases characterized by the accumulation of α-syn, including PD.

AB - The accumulation of misfolded proteins is a common pathological feature of many neurodegenerative disorders, including synucleinopathies such as Parkinson's disease (PD), which is characterized by the presence of α-synuclein (α-syn)-containing Lewy bodies. However, although recent studies have investigated α-syn accumulation and propagation in neurons, the molecular mechanisms underlying α-syn transmission have been largely unexplored. Here, we examined a monogenic form of synucleinopathy caused by loss-of-function mutations in lysosomal ATP13A2/PARK9. These studies revealed that lysosomal exocytosis regulates intracellular levels of α-syn in human neurons. Loss of PARK9 function in patient-derived dopaminergic neurons disrupted lysosomal Ca2+ homeostasis, reduced lysosomal Ca2+ storage, increased cytosolic Ca2+, and impaired lysosomal exocytosis. Importantly, this dysfunction in lysosomal exocytosis impaired α-syn secretion from both axons and soma, promoting α-syn accumulation. However, activation of the lysosomal Ca2+ channel transient receptor potential mucolipin 1 (TRPML1) was sufficient to upregulate lysosomal exocytosis, rescue defective α-syn secretion, and prevent α-syn accumulation. Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies.SIGNIFICANCE STATEMENT Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons. However, it is unclear what the mechanism might be. Here, we demonstrate a novel role for lysosomal exocytosis in clearing intracellular α-syn and show that impairment of this pathway by mutations in the PD-linked gene ATP13A2/PARK9 contributes to α-syn accumulation in human dopaminergic neurons. Importantly, upregulating lysosomal exocytosis by increasing lysosomal Ca2+ levels was sufficient to rescue defective α-syn secretion and accumulation in patient neurons. These studies identify lysosomal exocytosis as a potential therapeutic target in diseases characterized by the accumulation of α-syn, including PD.

KW - Kufor–Rakeb syndrome

KW - Parkinson's disease

KW - TRPML1

KW - alpha synuclein

KW - dopaminergic neuron

KW - lysosomal exocytosis

UR - http://www.scopus.com/inward/record.url?scp=85070055518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070055518&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.3085-18.2019

DO - 10.1523/JNEUROSCI.3085-18.2019

M3 - Article

VL - 39

SP - 5760

EP - 5772

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 29

ER -